TY - JOUR
T1 - Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients
T2 - First clinical and biomarker results from the BioDay registry
AU - Ariëns, Lieneke F M
AU - van der Schaft, Jorien
AU - Bakker, Daphne S
AU - Balak, Deepak
AU - Romeijn, Margreet L E
AU - Kouwenhoven, Tessa
AU - Kamsteeg, Marijke
AU - Giovannone, Barbara
AU - Drylewicz, Julia
AU - van Amerongen, Cynthia Catalina Aurora
AU - Delemarre, Evelien M
AU - Knol, Edward F
AU - van Wijk, Femke
AU - Nierkens, Stefan
AU - Thijs, Judith L
AU - Schuttelaar, Marie L A
AU - de Bruin-Weller, Marjolein S
N1 - Funding Information:
Funding information The BioDay registry is sponsored by Sanofi and Regeneron Pharmaceuticals.
Publisher Copyright:
© 2019 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - INTRODUCTION: Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.OBJECTIVE: To study the effect of 16-week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate-severe AD in daily practice.METHODS: Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen-week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI-50 (Eczema Area and Severity Index) or EASI-75, as well as patient-reported outcomes measures (Patient-Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty-one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks).RESULTS: In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult-to-treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI-50 and EASI-75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity-related serum biomarkers (TARC, PARC, periostin, and IL-22), eotaxin-1, and eotaxin-3 significantly decreased.CONCLUSION: Treatment with dupilumab significantly improved disease severity and decreased severity-related serum biomarkers in patients with very difficult-to-treat AD in a daily practice setting.
AB - INTRODUCTION: Dupilumab has recently been approved for the treatment of moderate to severe atopic dermatitis (AD) in adults. Daily practice data on dupilumab treatment are scarce.OBJECTIVE: To study the effect of 16-week treatment with dupilumab on clinical response and serum biomarkers in adult patients with moderate-severe AD in daily practice.METHODS: Data were extracted from the BioDay registry, a prospective multicenter registry. Sixteen-week clinical effectiveness of dupilumab was expressed as number of patients achieving EASI-50 (Eczema Area and Severity Index) or EASI-75, as well as patient-reported outcomes measures (Patient-Oriented Eczema Measure, Dermatology Life Quality Index, Numeric Rating Scale pruritus). Twenty-one biomarkers were measured in patients treated with dupilumab without concomitant use of oral immunosuppressive drugs at five different time points (baseline, 4, 8, 12, and 16 weeks).RESULTS: In total, 138 patients treated with dupilumab in daily practice were included. This cohort consisted of patients with very difficult-to-treat AD, including 84 (61%) patients who failed treatment on ≥2 immunosuppressive drugs. At week 16, the mean percent change in EASI score was 73%. The EASI-50 and EASI-75 were achieved by 114 (86%) and 82 (62%) patients after 16 weeks of treatment. The most reported side effect was conjunctivitis, occurring in 47 (34%) patients. During dupilumab treatment, disease severity-related serum biomarkers (TARC, PARC, periostin, and IL-22), eotaxin-1, and eotaxin-3 significantly decreased.CONCLUSION: Treatment with dupilumab significantly improved disease severity and decreased severity-related serum biomarkers in patients with very difficult-to-treat AD in a daily practice setting.
KW - Adult
KW - Anti-Allergic Agents/therapeutic use
KW - Antibodies, Monoclonal, Humanized/therapeutic use
KW - Biomarkers/blood
KW - Cohort Studies
KW - Dermatitis, Atopic/drug therapy
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Registries
KW - Treatment Outcome
KW - biomarkers
KW - atopic dermatitis
KW - dupilumab
KW - daily practice
KW - disease severity
UR - http://www.scopus.com/inward/record.url?scp=85074852061&partnerID=8YFLogxK
U2 - 10.1111/all.14080
DO - 10.1111/all.14080
M3 - Article
C2 - 31593343
SN - 0105-4538
VL - 75
SP - 116
EP - 126
JO - Allergy
JF - Allergy
IS - 1
ER -